Nifty
Sensex
:
:
18726.40
63142.96
127.40 (0.69%)
350.08 (0.56%)

Pharmaceuticals & Drugs

Rating :
48/99

BSE: 526953 | NSE: VENUSREM

228.55
07-Jun-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 228.55
  • 233.85
  • 226.00
  • 228.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  107658
  •  247.32
  •  264.00
  •  145.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 305.84
  • 11.51
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 298.29
  • N/A
  • 0.66

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 41.76%
  • 1.68%
  • 49.24%
  • FII
  • DII
  • Others
  • 1%
  • 0.00%
  • 6.32%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.48
  • 9.96
  • 20.83

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.38
  • 9.49
  • 8.76

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -3.36
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.46
  • 4.83
  • 8.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.43
  • 0.53
  • 0.80

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.67
  • 7.50
  • 6.90

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
155.64
142.45
9.26%
116.90
124.34
-5.98%
139.89
202.56
-30.94%
143.08
129.81
10.22%
Expenses
131.03
136.91
-4.29%
108.80
111.91
-2.78%
126.92
175.26
-27.58%
128.57
112.99
13.79%
EBITDA
24.61
5.54
344.22%
8.10
12.43
-34.84%
12.97
27.30
-52.49%
14.51
16.82
-13.73%
EBIDTM
15.81%
3.89%
6.93%
10.00%
9.27%
13.48%
10.14%
12.96%
Other Income
3.41
2.25
51.56%
3.81
1.22
212.30%
1.79
2.89
-38.06%
1.44
1.96
-26.53%
Interest
0.00
0.00
0
0.15
0.31
-51.61%
0.00
0.03
-100.00%
0.26
0.14
85.71%
Depreciation
8.29
7.56
9.66%
7.22
8.64
-16.44%
8.99
8.71
3.21%
7.80
8.62
-9.51%
PBT
19.73
0.23
8,478.26%
4.54
4.70
-3.40%
5.77
21.46
-73.11%
7.89
10.02
-21.26%
Tax
8.67
0.00
0
1.25
-0.95
-
0.44
-1.69
-
1.00
-1.68
-
PAT
11.06
0.23
4,708.70%
3.29
5.65
-41.77%
5.33
23.15
-76.98%
6.89
11.70
-41.11%
PATM
7.11%
0.16%
2.81%
4.54%
3.81%
11.43%
4.82%
9.01%
EPS
8.27
0.17
4,764.71%
2.46
4.23
-41.84%
3.99
17.32
-76.96%
5.15
8.75
-41.14%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
555.51
598.65
548.12
339.33
321.89
372.41
400.04
418.27
463.99
541.56
468.64
Net Sales Growth
-7.29%
9.22%
61.53%
5.42%
-13.57%
-6.91%
-4.36%
-9.85%
-14.32%
15.56%
 
Cost Of Goods Sold
331.00
385.45
340.79
174.31
181.95
205.08
227.07
238.51
268.94
300.00
262.26
Gross Profit
224.51
213.20
207.33
165.02
139.94
167.33
172.97
179.77
195.05
241.55
206.38
GP Margin
40.42%
35.61%
37.83%
48.63%
43.47%
44.93%
43.24%
42.98%
42.04%
44.60%
44.04%
Total Expenditure
495.32
536.54
494.35
298.52
289.37
332.94
349.32
337.11
374.81
403.33
348.53
Power & Fuel Cost
-
4.71
4.58
4.73
4.86
4.29
4.14
4.01
3.80
3.38
3.05
% Of Sales
-
0.79%
0.84%
1.39%
1.51%
1.15%
1.03%
0.96%
0.82%
0.62%
0.65%
Employee Cost
-
52.33
46.02
46.02
42.10
39.31
34.27
32.44
32.36
30.45
27.30
% Of Sales
-
8.74%
8.40%
13.56%
13.08%
10.56%
8.57%
7.76%
6.97%
5.62%
5.83%
Manufacturing Exp.
-
31.57
22.86
20.84
21.01
36.10
42.48
15.70
17.29
22.10
20.61
% Of Sales
-
5.27%
4.17%
6.14%
6.53%
9.69%
10.62%
3.75%
3.73%
4.08%
4.40%
General & Admin Exp.
-
16.91
16.45
17.57
11.85
13.52
13.26
11.97
15.67
14.74
11.82
% Of Sales
-
2.82%
3.00%
5.18%
3.68%
3.63%
3.31%
2.86%
3.38%
2.72%
2.52%
Selling & Distn. Exp.
-
45.56
63.64
35.05
27.60
34.65
28.10
34.48
36.75
32.65
23.50
% Of Sales
-
7.61%
11.61%
10.33%
8.57%
9.30%
7.02%
8.24%
7.92%
6.03%
5.01%
Miscellaneous Exp.
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
23.50
% Of Sales
-
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
EBITDA
60.19
62.11
53.77
40.81
32.52
39.47
50.72
81.16
89.18
138.23
120.11
EBITDA Margin
10.84%
10.38%
9.81%
12.03%
10.10%
10.60%
12.68%
19.40%
19.22%
25.52%
25.63%
Other Income
10.45
8.31
19.63
5.31
6.09
2.39
4.28
2.01
0.68
0.47
0.44
Interest
0.41
0.48
13.02
13.34
25.41
35.56
36.38
37.98
41.21
29.40
24.63
Depreciation
32.30
33.53
35.28
32.01
33.98
33.83
40.26
41.68
46.00
40.22
33.08
PBT
37.93
36.41
25.11
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
62.84
Tax
11.36
-4.32
-13.21
1.96
-1.15
3.16
-4.56
1.81
-2.51
4.78
5.53
Tax Rate
29.95%
-11.86%
-27.21%
-24.41%
3.87%
-11.48%
21.07%
51.57%
-94.72%
6.92%
8.80%
PAT
26.57
40.72
61.77
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
57.31
PAT before Minority Interest
26.57
40.72
61.77
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
57.31
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
4.78%
6.80%
11.27%
-2.95%
-8.88%
-8.24%
-4.27%
0.41%
1.11%
11.87%
12.23%
PAT Growth
-34.77%
-34.08%
-
-
-
-
-
-67.05%
-91.98%
12.20%
 
EPS
19.83
30.39
46.10
-7.46
-21.32
-22.90
-12.75
1.27
3.85
47.99
42.77

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
440.45
400.28
323.37
332.52
361.91
388.67
437.62
456.68
461.61
379.13
Share Capital
13.37
12.34
12.34
12.34
12.34
12.34
11.44
11.44
11.44
10.54
Total Reserves
427.08
374.19
311.03
320.18
349.57
376.33
426.18
445.24
450.17
363.81
Non-Current Liabilities
45.95
58.12
95.82
136.68
158.47
179.52
212.05
221.55
161.75
147.18
Secured Loans
0.00
0.09
24.19
61.29
86.60
112.69
134.57
150.95
114.76
103.89
Unsecured Loans
38.68
46.74
47.87
54.73
50.84
49.13
56.47
51.34
25.22
25.22
Long Term Provisions
7.95
7.38
6.63
5.32
4.50
4.29
3.79
3.78
3.31
2.91
Current Liabilities
92.74
97.45
224.58
263.62
230.38
196.81
193.14
162.83
210.99
191.25
Trade Payables
54.29
71.36
36.70
36.00
29.33
29.73
25.14
29.56
31.22
18.76
Other Current Liabilities
33.64
21.10
101.70
110.30
78.47
46.16
42.71
15.96
54.70
58.18
Short Term Borrowings
4.06
4.30
85.58
112.80
121.26
119.16
123.32
115.40
110.08
95.68
Short Term Provisions
0.75
0.68
0.61
4.52
1.32
1.76
1.97
1.91
14.99
18.63
Total Liabilities
579.14
555.85
643.77
732.82
750.76
765.00
842.81
841.06
834.35
717.56
Net Block
240.94
261.68
289.37
364.45
389.20
406.18
452.48
443.65
439.46
401.42
Gross Block
612.50
616.32
623.96
707.02
702.77
686.50
679.57
641.12
587.38
511.00
Accumulated Depreciation
371.57
354.63
334.59
342.57
313.57
280.32
227.09
197.47
147.93
109.58
Non Current Assets
301.10
321.82
349.77
467.39
490.50
505.60
565.75
607.85
562.24
491.97
Capital Work in Progress
25.23
25.11
24.63
64.76
64.76
66.25
80.37
78.30
67.80
47.81
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
34.93
35.03
35.77
38.18
36.53
33.17
32.90
85.91
54.98
42.74
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
278.04
234.03
294.00
265.43
260.27
259.41
277.07
233.21
272.11
225.58
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
125.64
119.99
141.12
142.73
138.17
140.60
143.29
142.87
142.26
128.03
Sundry Debtors
38.60
32.04
30.69
38.04
47.27
47.29
61.59
63.22
64.99
47.11
Cash & Bank
50.40
31.42
2.13
2.81
3.98
3.56
7.07
3.62
4.41
6.36
Other Current Assets
63.40
5.70
55.72
5.15
70.84
67.96
65.12
23.51
60.47
44.08
Short Term Loans & Adv.
58.39
44.88
64.34
76.70
66.00
67.96
65.12
23.51
60.47
44.08
Net Current Assets
185.30
136.59
69.43
1.81
29.88
62.59
83.93
70.38
61.12
34.33
Total Assets
579.14
555.85
643.77
732.82
750.77
765.01
842.82
841.06
834.35
717.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
41.00
131.84
77.60
45.33
31.19
58.93
46.88
67.80
52.65
52.15
PBT
36.41
25.11
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
62.84
Adjustment
26.33
21.89
41.56
60.72
66.24
70.61
56.41
83.56
37.21
40.72
Changes in Working Capital
-21.74
61.39
20.82
5.37
-7.52
9.96
-13.04
-18.40
-53.65
-51.41
Cash after chg. in Working capital
41.00
108.39
63.16
45.33
31.19
58.93
46.88
67.80
52.65
52.15
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
23.44
14.44
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-16.63
56.49
-4.75
-11.33
-11.48
-18.32
2.92
-67.18
-94.66
-103.89
Net Fixed Assets
3.42
7.56
124.42
-5.05
-11.74
18.95
-50.18
-67.39
-93.77
-101.63
Net Investments
0.00
0.00
0.00
0.00
28.60
0.00
0.00
0.00
0.00
0.00
Others
-20.05
48.93
-129.17
-6.28
-28.34
-37.27
53.10
0.21
-0.89
-2.26
Cash from Financing Activity
-9.48
-162.24
-73.00
-35.17
-39.23
-44.13
-46.35
-1.42
40.06
55.15
Net Cash Inflow / Outflow
14.90
26.09
-0.15
-1.17
-19.52
-3.51
3.46
-0.79
-1.95
3.41
Opening Cash & Equivalents
28.88
1.94
2.03
3.98
0.00
7.07
3.62
4.41
6.36
2.95
Closing Cash & Equivalent
43.26
28.88
1.94
2.81
-19.52
3.56
7.07
3.62
4.41
6.36

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
329.50
313.18
262.01
269.42
293.23
314.92
382.47
399.13
403.43
355.10
ROA
7.18%
10.30%
-1.45%
-3.85%
-4.05%
-2.12%
0.20%
0.62%
8.29%
8.87%
ROE
9.85%
17.40%
-3.05%
-8.23%
-8.18%
-4.13%
0.38%
1.12%
15.38%
17.04%
ROCE
7.89%
12.37%
0.90%
-0.67%
1.17%
2.00%
5.35%
5.74%
14.06%
14.85%
Fixed Asset Turnover
0.97
0.88
0.51
0.46
0.54
0.59
0.63
0.76
0.99
1.00
Receivable days
21.54
20.89
36.97
48.37
46.34
49.67
54.45
50.42
37.72
33.88
Inventory Days
74.88
86.94
152.66
159.26
136.61
129.51
124.86
112.15
90.94
87.34
Payable days
59.49
57.86
42.82
37.91
30.30
26.74
26.74
27.25
21.28
15.09
Cash Conversion Cycle
36.93
49.96
146.80
169.72
152.65
152.44
152.57
135.32
107.37
106.14
Total Debt/Equity
0.10
0.13
0.68
0.90
0.85
0.80
0.77
0.70
0.63
0.72
Interest Cover
76.69
4.73
0.40
-0.17
0.23
0.41
1.09
1.06
3.35
3.55

News Update:


  • Venus Remedies gets GMP certification from Ukraine
    7th Jun 2023, 12:17 PM

    This international GMP approval, the 27th for Venus Remedies, will also enable the company to expand its product portfolio globally

    Read More
  • Venus Remedies secures GMP certification from Kenya for all production facilities in Baddi
    23rd May 2023, 12:27 PM

    With this, the number of international GMP certifications for Venus Remedies has gone up to 25

    Read More
  • Venus Remedies receives renewal of recognition for in-house R&D excellence by DSIR
    16th May 2023, 11:27 AM

    The company has consistently invested in research and development

    Read More
  • Venus Remedies secures marketing authorization from UK MHRA for Cisplatin
    25th Apr 2023, 15:41 PM

    The registration for Cisplatin will also expedite the process of registering the oncology products of Venus Remedies in many other countries

    Read More
  • Venus Remedies receives GMP certification from Saudi Arabia
    27th Feb 2023, 10:38 AM

    The company has received GMP certification for all its production facilities at its unit in Baddi, Himachal Pradesh

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.